Nature biotechnology
-
Nature biotechnology · Feb 2007
ReviewManaging conflicts of interest: a survival guide for biotechs.
Conflicts of interest in research can affect a company's ability to move a product through the approval processor attract investment. Avoid the pitfalls by taking pro-active steps to manage these risks.
-
Nature biotechnology · Jan 2007
ReviewAnimal cloning and the FDA--the risk assessment paradigm under public scrutiny.
The evidence gathered thus far--ultimately to be published in the Draft Risk Assessment on Animal Cloning--indicates that there are no unique risks associated with animal cloning.
-
Nature biotechnology · Dec 2006
The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT.
Bacteriolytic anti-cancer therapies employ attenuated bacterial strains that selectively proliferate within tumors. Clostridium novyi-NT spores represent one of the most promising of these agents, as they generate potent anti-tumor effects in experimental animals. ⋯ The genomic sequence was used to facilitate the detection of transcripts expressed at various stages of the life cycle of this bacterium in vitro as well as in infections of tumors in vivo. Through this analysis, we found that C. novyi-NT spores contained mRNA and that the spore transcripts were distinct from those in vegetative forms of the bacterium.
-
Is uncertainty concerning the regulation of antimicrobial drug trials stifling investment in infectious disease treatments? Here, experts from a large pharma company and a biotech firm provide their perspectives.
-
Contrary to conventional thinking, there are compelling reasons for investors to consider early-stage life science ventures, especially in the context of a maturing biotech business 'ecosystem'.